Kunming Longjin Pharmaceutical Co Ltd (002750) - Total Assets
Based on the latest financial reports, Kunming Longjin Pharmaceutical Co Ltd (002750) holds total assets worth CN¥555.15 Million CNY (≈ $81.24 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Kunming Longjin Pharmaceutical Co Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
Kunming Longjin Pharmaceutical Co Ltd - Total Assets Trend (2011–2024)
This chart illustrates how Kunming Longjin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. Explore 002750 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Kunming Longjin Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Kunming Longjin Pharmaceutical Co Ltd's total assets of CN¥555.15 Million consist of 58.9% current assets and 41.1% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 45.6% |
| Accounts Receivable | CN¥8.75 Million | 1.5% |
| Inventory | CN¥21.86 Million | 3.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥58.20 Million | 10.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Kunming Longjin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Kunming Longjin Pharmaceutical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kunming Longjin Pharmaceutical Co Ltd's current assets represent 58.9% of total assets in 2024, an increase from 37.5% in 2011.
- Cash Position: Cash and equivalents constituted 45.6% of total assets in 2024, up from 22.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 7.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 10.1% of total assets.
Kunming Longjin Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Kunming Longjin Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Kunming Longjin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.94 | 5.97 | 5.30 |
| Quick Ratio | 7.29 | 5.57 | 4.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥271.92 Million | CN¥327.68 Million | CN¥384.35 Million |
Kunming Longjin Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Kunming Longjin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.51 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -9.1% |
| Total Assets | CN¥574.40 Million |
| Market Capitalization | $34.58 Million USD |
Valuation Analysis
Below Book Valuation: The market values Kunming Longjin Pharmaceutical Co Ltd's assets below their book value (0.06x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Kunming Longjin Pharmaceutical Co Ltd's assets decreased by 9.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual total assets of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥574.40 Million ≈ $84.05 Million |
-9.06% |
| 2023-12-31 | CN¥631.63 Million ≈ $92.43 Million |
-15.47% |
| 2022-12-31 | CN¥747.21 Million ≈ $109.34 Million |
-9.68% |
| 2021-12-31 | CN¥827.28 Million ≈ $121.06 Million |
-1.72% |
| 2020-12-31 | CN¥841.76 Million ≈ $123.18 Million |
+4.32% |
| 2019-12-31 | CN¥806.89 Million ≈ $118.07 Million |
+2.46% |
| 2018-12-31 | CN¥787.55 Million ≈ $115.24 Million |
+0.30% |
| 2017-12-31 | CN¥785.23 Million ≈ $114.90 Million |
+3.36% |
| 2016-12-31 | CN¥759.68 Million ≈ $111.17 Million |
+8.70% |
| 2015-12-31 | CN¥698.86 Million ≈ $102.27 Million |
+60.44% |
| 2014-12-31 | CN¥435.59 Million ≈ $63.74 Million |
-1.58% |
| 2013-12-31 | CN¥442.56 Million ≈ $64.76 Million |
+20.24% |
| 2012-12-31 | CN¥368.05 Million ≈ $53.86 Million |
+28.08% |
| 2011-12-31 | CN¥287.36 Million ≈ $42.05 Million |
-- |
About Kunming Longjin Pharmaceutical Co Ltd
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial… Read more